Par Pharmaceutical Companies, Inc.™ (NYSE:PRX) develops, manufactures and markets generic drugs and innovative proprietary pharmaceuticals for specialty markets.

Par’s Generics Division is committed to providing high-quality pharmaceuticals that are affordable and accessible to patients. According to IMS Health, Par ranks in the top 10 in U.S. sales among all generic drug companies. The company currently manufactures, markets or licenses generic prescription drugs in 85 product families.

Par's Branded Products Division was launched in 2005 with the approval of Megace^® ES. In September 2007, it was renamed Strativa Pharmaceuticals. Megace ES is indicated for the treatment of anorexia, cachexia, or unexplained significant weight loss in AIDS patients and was conceived and developed by Par's Generic Division and launched in 2005.

Strativa Pharmaceuticals, with an experienced branded management team, boasts strong commercial infrastructure and is deployed to over 80% of the treaters in the supportive care segment.

To date, Strativa Pharmaceuticals in-licensed four proprietary drugs in late-stage development: Zensana™ (ondansetron HCL) Oral Spray, Loramyc™ (miconazole Lauriad^®), ONCONASE^® (ranpirnase), and thin film ondansetron. Ondansetron is used to prevent nausea and vomiting after chemotherapy, radiation and surgery, and following successful development and approval, Zensana could be among the first in its class of antiemetic therapies to be available in an oral spray form. Loramyc is an innovative antifungal therapy currently in Phase III development for the treatment of oropharyngeal candidiasis, an opportunistic infection commonly found in immune-compromised patients, including those with HIV and cancer. ONCONASE^® (ranpirnase) is in Phase III development for the treatment of unresectable malignant mesothelioma, a rare cancer affecting the lung usually associated with exposure to asbestos.  Ondansetron thin film formulation is a new oral formulation in development for the prevention of chemotherapy-induced nausea and vomiting, nausea and vomiting associated with radiotherapy, and post-operative nausea and vomiting.

Each of these development-stage products was in-licensed following a rigorous due diligence process and with the goal of leveraging Strativa's management and commercial infrastructure.